OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 114 filers reported holding OCULAR THERAPEUTIX INC in Q3 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $233,619 | -10.8% | 74,401 | +46.6% | 0.00% | – |
| Q2 2023 | $261,942 | +236.9% | 50,764 | +244.0% | 0.00% | – |
| Q1 2023 | $77,759 | +112.0% | 14,755 | +13.0% | 0.00% | – |
| Q4 2022 | $36,685 | -74.7% | 13,055 | -62.6% | 0.00% | – |
| Q3 2022 | $145,000 | +16.9% | 34,873 | +13.1% | 0.00% | – |
| Q2 2022 | $124,000 | +15.9% | 30,828 | +42.8% | 0.00% | – |
| Q1 2022 | $107,000 | -77.2% | 21,584 | -75.4% | 0.00% | -100.0% |
| Q4 2021 | $470,000 | +98.3% | 87,602 | +269.2% | 0.00% | – |
| Q3 2021 | $237,000 | -34.7% | 23,729 | -7.3% | 0.00% | -100.0% |
| Q2 2021 | $363,000 | -15.0% | 25,593 | -1.6% | 0.00% | 0.0% |
| Q1 2021 | $427,000 | -17.1% | 25,999 | +4.5% | 0.00% | 0.0% |
| Q4 2020 | $515,000 | +221.9% | 24,890 | +18.4% | 0.00% | – |
| Q3 2020 | $160,000 | -61.3% | 21,014 | -57.6% | 0.00% | -100.0% |
| Q2 2020 | $413,000 | +436.4% | 49,619 | +220.6% | 0.00% | – |
| Q1 2020 | $77,000 | – | 15,476 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |